8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 21, 2004

BRUKER BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	000-30833	04-3110160
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
40 Manning Road Billerica, MA 01821
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (978) 663-3660

Item 12.   Results of Operations and Financial Condition

On April 21, 2004, Bruker BioSciences Corporation issued a press release announcing its preliminary financial results for the first fiscal quarter ended March 31, 2004.  A copy of the related press release is attached hereto as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Exhibit Number	Description
99.1	Bruker BioSciences Corporation press release dated April 21, 2004.

The information provided in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

2

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER BIOSCIENCES CORPORATION (Registrant)
Date:  April 21, 2004	By:	/s/ Laura Francis
		Laura Francis Chief Financial Officer and Treasurer

3

Exhibit Index

Number	Description
99.1	Bruker BioSciences Corporation press release dated April 21, 2004.

4

EX-99.1

Exhibit 99.1

Bruker BioSciences Announces Preliminary First Quarter

Results; Full Earnings Release Planned for May 4, 2004

Billerica, Massachusetts  –  April 21, 2004  –  Bruker BioSciences Corporation (NASDAQ: BRKR) today announced preliminary financial results for the first quarter which ended on March 31, 2004.  For the first quarter of 2004, the Company expects revenue to be between $68.0 million and $69.0 million, and fully diluted earnings per share to be approximately $0.01, both within the Company's previous first quarter guidance.  In accordance with its March 2, 2004 press release, the Company continues to expect revenue of $290 to $300 million and adjusted EPS of $0.07 to $0.09 per diluted share for the full year 2004, based upon strength in bookings and backlog.

Bruker BioSciences plans to release its complete first quarter 2004 financial results on Tuesday, May 4, 2004 after the market closes.  The Company will host an operator-assisted earnings conference call at 8 a.m. Eastern Daylight Time the following morning, on Wednesday, May 5.  To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.

Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada.  Investors should refer to the Bruker BioSciences Quarterly Earnings Call.  A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 19810944.

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology.  For more information, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company’s products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our

current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.

Contact:	Michael Willett, Investor and Public Relations
	Tel:  (978) 663-3660
	Email: ir@bruker-biosciences.com